Oramed Pharmaceuticl (ORMP) 9.25 $ORMP
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Oramed Pharmaceuticals Presents Data from Phase IIa Trial with ORMD-0801 in Type 2 Diabetes at the 2014 Diabetes Summit
PR Newswire - Thu Apr 24, 1:30PM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2 diabetes patients. The preliminary results of this trial were originally announced on January 30, 2014. The results are being presented today by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, at the 2014 GTC Diabetes Summit, taking place in Cambridge, Massachusetts, USA. The trial was conducted in the United States under a Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Oramed secures patent for oral administration of insulin in Hong Kong
M2 - Fri Apr 11, 7:11AM CDT
Israel-based Oramed Pharmaceuticals (NasdaqCM:ORMP) revealed on Thursday the receipt of a patent for its invention "Methods and Compositions for Oral Administrations of Proteins" in Hong Kong.
Oramed Granted Patent in Hong Kong for Oral Administration of Insulin
PR Newswire - Thu Apr 10, 7:10AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Hong Kong has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
A Speculative Biotech Catalyst Trade: ORMP
at The Street - Fri Mar 28, 8:23AM CDT
This beaten-down biotech stock could be ripe for a rebound.
Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes
PR Newswire - Thu Mar 27, 7:45AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).
5 Stocks With Big Insider Buying
at The Street - Wed Mar 26, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals
Marketwire - Thu Mar 20, 8:30AM CDT
LifeSci Advisors, LLC and Oramed Pharmaceuticals (NASDAQ: ORMP)
Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide
PR Newswire - Tue Mar 11, 7:30AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.
Oramed to Present at Upcoming Conferences
PR Newswire - Thu Mar 06, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company will present at the following conferences in March 2014:
Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014
PR Newswire - Mon Mar 03, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
PeopleLinx Achieves 300% Sales Growth in 2013 and Signs Over 40 Top Brands
PR Newswire - Tue Feb 18, 8:03AM CST
PeopleLinx, provider of automated marketing and training solutions for LinkedIn, announced today that the company achieved 300% sales growth in 2013 and signed over 40 new brands. As brands create new sales, marketing and recruitment opportunities through LinkedIn, PeopleLinx has met demand for software that can manage employee training, content sharing and analytics at enterprise scale.
AutoCanada Inc. Announces its Twelfth Consecutive Quarterly Dividend Increase
PR Newswire - Fri Feb 14, 11:30AM CST
AutoCanada Inc. ("AutoCanada"
(TSX:ACQ) today announced that its Board of Directors has declared a quarterly eligible dividend of $0.22 per common share, an increase of 4.8% from the previous quarterly dividend of $0.21 per common share. The dividend is payable on March 17, 2014 to shareholders of record at the close of business on February 28, 2014. The declared dividend represents a rate of $0.88 per share on an annualized basis.
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Oramed Pharmaceuticals Presents Data from Phase IIa Trial with ORMD-0801 in Type 2 Diabetes at the 2014 Diabetes Summit
PR Newswire - Thu Apr 24, 1:30PM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2 diabetes patients. The preliminary results of this trial were originally announced on January 30, 2014. The results are being presented today by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, at the 2014 GTC Diabetes Summit, taking place in Cambridge, Massachusetts, USA. The trial was conducted in the United States under a Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Oramed secures patent for oral administration of insulin in Hong Kong
M2 - Fri Apr 11, 7:11AM CDT
Israel-based Oramed Pharmaceuticals (NasdaqCM:ORMP) revealed on Thursday the receipt of a patent for its invention "Methods and Compositions for Oral Administrations of Proteins" in Hong Kong.
Oramed Granted Patent in Hong Kong for Oral Administration of Insulin
PR Newswire - Thu Apr 10, 7:10AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Hong Kong has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
A Speculative Biotech Catalyst Trade: ORMP
at The Street - Fri Mar 28, 8:23AM CDT
This beaten-down biotech stock could be ripe for a rebound.
Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes
PR Newswire - Thu Mar 27, 7:45AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).
5 Stocks With Big Insider Buying
at The Street - Wed Mar 26, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals
Marketwire - Thu Mar 20, 8:30AM CDT
LifeSci Advisors, LLC and Oramed Pharmaceuticals (NASDAQ: ORMP)
Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide
PR Newswire - Tue Mar 11, 7:30AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.
Oramed to Present at Upcoming Conferences
PR Newswire - Thu Mar 06, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company will present at the following conferences in March 2014:
Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014
PR Newswire - Mon Mar 03, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
PeopleLinx Achieves 300% Sales Growth in 2013 and Signs Over 40 Top Brands
PR Newswire - Tue Feb 18, 8:03AM CST
PeopleLinx, provider of automated marketing and training solutions for LinkedIn, announced today that the company achieved 300% sales growth in 2013 and signed over 40 new brands. As brands create new sales, marketing and recruitment opportunities through LinkedIn, PeopleLinx has met demand for software that can manage employee training, content sharing and analytics at enterprise scale.
AutoCanada Inc. Announces its Twelfth Consecutive Quarterly Dividend Increase
PR Newswire - Fri Feb 14, 11:30AM CST
AutoCanada Inc. ("AutoCanada"
(TSX:ACQ) today announced that its Board of Directors has declared a quarterly eligible dividend of $0.22 per common share, an increase of 4.8% from the previous quarterly dividend of $0.21 per common share. The dividend is payable on March 17, 2014 to shareholders of record at the close of business on February 28, 2014. The declared dividend represents a rate of $0.88 per share on an annualized basis. 
